About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: LXRX
- CUSIP: 52887210
- Previous Close: $15.29
- 50 Day Moving Average: $14.53
- 200 Day Moving Average: $15.79
- 52-Week Range: $8.37 - $19.62
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.49
- P/E Growth: -0.18
- Market Cap: $1.59B
- Outstanding Shares: 104,036,000
- Beta: 0.6
- Net Margins: -11.87%
- Return on Equity: -9.46%
- Return on Assets: -3.80%
Companies Related to Lexicon Pharmaceuticals:
- Debt-to-Equity Ratio: 0.46%
- Current Ratio: 2.34%
- Quick Ratio: 2.34%
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?
7 equities research analysts have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their forecasts range from $16.00 to $33.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $24.33 in the next twelve months.
When will Lexicon Pharmaceuticals announce their earnings?
Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/17/2017)
Needham & Company LLC analysts commented, "Telotristat is under review by FDA for treatment of Carcinoid Syndrome. We expect approval by 2/28/17 PDUFA date. Phase 3 registration trial met its primary endpoint of reduction in BM frequency, with trends towards reduction in flushing and abdominal pain. No FDA AdCom mtg was held. Lexicon has built commercial infrastructure and plans to market telotristat by itself. We estimate peak U.S. sales in the range of $250-300M. Most ex-U.S. rights to telotristat were out- licensed to Ipsen, which has submitted an MAA." (1/27/2017)
Who owns Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (1.53%), Loomis Sayles & Co. L P (0.81%), Teachers Retirement System of The State of Kentucky (0.54%), GSA Capital Partners LLP (0.14%) and AQR Capital Management LLC (0.09%).
Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, Loomis Sayles & Co. L P, Pacad Investment Ltd., AQR Capital Management LLC, Tudor Investment Corp Et Al and Paradigm Asset Management Co. LLC.
Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Advisory Research Inc., GSA Capital Partners LLP, A.R.T. Advisors LLC, FMR LLC and Numeric Investors LLC.
How do I buy Lexicon Pharmaceuticals stock?
Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Lexicon Pharmaceuticals stock cost?
One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $15.29.